title: Reappraising first-line treatment in glaucoma management.
abstract: Despite treatment, glaucoma patients may still suffer vision loss because of inadequate control of intraocular pressure or late presentation. This article reviews the latest evidence supporting a reappraisal of first-line treatment in the management of glaucoma, including a review of latanoprost, recently approved for first-line treatment of glaucoma and ocular hypertension.
mesh_terms: D000577:Amides; D000959:Antihypertensive Agents / Q000627:therapeutic use; D000069580:Bimatoprost; D000068438:Brimonidine Tartrate; D003008:Cloprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D000077338:Latanoprost; D008055:Lipids / Q000627:therapeutic use; D011453:Prostaglandins / Q000627:therapeutic use; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use; D011810:Quinoxalines / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D000069557:Travoprost
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D008055:Lipids; D011453:Prostaglandins; D011461:Prostaglandins F, Synthetic; D011810:Quinoxalines; D013449:Sulfonamides; D013876:Thiophenes; D003008:Cloprostenol; D000068438:Brimonidine Tartrate; C072630:isopropyl unoprostone; D000077338:Latanoprost; C062765:dorzolamide; D015237:Dinoprost; D000069580:Bimatoprost; D000069557:Travoprost